道学气
发表于 2025-3-23 12:51:56
http://reply.papertrans.cn/39/3890/388968/388968_11.png
aviator
发表于 2025-3-23 17:51:27
http://reply.papertrans.cn/39/3890/388968/388968_12.png
旧石器时代
发表于 2025-3-23 19:08:51
Group-Sequential Clinical Trials with Multiple Co-Objectives
爵士乐
发表于 2025-3-23 23:12:18
http://reply.papertrans.cn/39/3890/388968/388968_14.png
POWER
发表于 2025-3-24 02:44:49
http://reply.papertrans.cn/39/3890/388968/388968_15.png
CRATE
发表于 2025-3-24 10:00:36
http://reply.papertrans.cn/39/3890/388968/388968_16.png
Overdose
发表于 2025-3-24 11:21:45
http://reply.papertrans.cn/39/3890/388968/388968_17.png
synovial-joint
发表于 2025-3-24 14:58:27
Controversies and Future Challenges,her design features. This includes clinical trials with more than two interventions (e.g., dose-selection clinical trials): trials with time-to-event endpoints and trials with targeted subgroups and enrichment clinical trial designs. In Chap. ., we briefly discuss the issues in the design of these trials.
去世
发表于 2025-3-24 19:15:24
http://reply.papertrans.cn/39/3890/388968/388968_19.png
Gyrate
发表于 2025-3-24 23:16:05
Future Developments,her design features. This includes clinical trials with more than two interventions (e.g., dose-selection clinical trials): trials with time-to-event endpoints and trials with targeted subgroups and enrichment clinical trial designs. In Chap. ., we briefly discuss the issues in the design of these trials.